Want to see PTGX full AI Analyst Report?
PTGX Stock Chart & Stats
$150.59
$3.38(2.48%)
At close: 4:00 PM EDT
$150.59
$3.38(2.48%)
Day’s Range― - ―
52-Week Range$73.08 - $160.81
Previous CloseN/A
Volume130.00
Average Volume (3M)767.08K
Market Cap
$8.70B
Enterprise Value$7.93B
Total Cash (Recent Filing)$782.58M
Total Debt (Recent Filing)$9.22M
Price to Earnings (P/E)110.4
Beta-0.08
Next Earnings
Nov 05, 2026EPS Estimate
2.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding64,708,280
10 Day Avg. Volume880,387
30 Day Avg. Volume767,081
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.03
Price to Sales (P/S)120.66
P/FCF Ratio99.01
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue28.12
Enterprise Value/Gross Profit28.16
Enterprise Value/Ebitda92.35
Forecast
1Y Price Target
$174.17Price Target Upside15.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)4.6
Revenue Forecast (FY)$542.76M
Bulls Say, Bears Say
Bulls Say
Commercial And Partnership ProgressICOTYDE’s launch creates a commercial revenue stream beyond clinical-stage development, while the milestone demonstrates partner economic support. The rusfertide transaction also improved royalties and generated substantial cash, strengthening the company’s ability to fund additional pipeline programs.
Conservative Balance SheetVery low leverage limits debt-servicing pressure and preserves financial flexibility for clinical development, partnerships, and commercial investment. The substantial equity base and asset position provide resilience if collaboration receipts or product revenues fluctuate over the next several quarters.
Current Profitability And Cash GenerationThe latest period shows a meaningful financial inflection, with revenue growth translating into positive earnings and cash generation. High gross margins and free cash flow broadly in line with net income indicate that recent profitability is supported by cash economics rather than accounting earnings alone.
Bears Say
Earnings VolatilityThe sharp shift from significant losses to recent profit makes forward earnings durability uncertain. Such volatility can complicate budgeting and capital allocation, and it suggests that future results may depend heavily on the timing and size of milestones, licensing receipts, or other irregular revenue.
Dependence On Collaboration RevenueA collaboration-led revenue model can produce substantial receipts but also makes reported performance dependent on partner decisions and clinical, regulatory, or commercial milestones. This creates less predictable revenue visibility than a mature portfolio of recurring product sales.
Cash Flow Normalization RiskRecent positive cash generation is encouraging, but the historical pattern shows that cash flow has not been consistently self-sustaining. The sharp decline in the latest growth rate raises the possibility that current cash performance may normalize after unusually strong collaboration-related receipts.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $73.08 and its highest was $160.81 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $8.70B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Aug 05, 2026. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.213 by $0.077.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is 2.39.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 64,708,280 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of $2.29 in its last earnings report, beating expectations of $2.213. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$174.17 (15.66% Upside)
$174.17 (15.66% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 86%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 214.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $33.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.47%
12-Months-Change
Fundamentals
Return on Equity
12.03%
Trailing 12-Months
Asset Growth
23.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
PTGX Stock 12 Month Forecast
Average Price Target
$174.17
▲(15.66% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Spyre Therapeutics
―
Immunovant
―
Vera Therapeutics
―
Abivax SA Sponsored ADR
―
Ownership Overview
1.18% Insiders
26.44% Mutual Funds
0.40% Other Institutional Investors
43.74% Public Companies and
Individual Investors